A detailed history of 180 Wealth Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, 180 Wealth Advisors, LLC holds 912 shares of VRTX stock, worth $423,678. This represents 0.07% of its overall portfolio holdings.

Number of Shares
912
Previous 957 4.7%
Holding current value
$423,678
Previous $448,000 5.36%
% of portfolio
0.07%
Previous 0.08%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

SELL
$460.0 - $505.78 $20,700 - $22,760
-45 Reduced 4.7%
912 $424,000
Q2 2024

Jul 16, 2024

SELL
$392.81 - $485.53 $7,463 - $9,225
-19 Reduced 1.95%
957 $448,000
Q1 2024

Apr 15, 2024

BUY
$407.69 - $446.08 $119,453 - $130,701
293 Added 42.9%
976 $407,000
Q3 2023

Oct 31, 2023

BUY
$338.18 - $362.46 $676 - $724
2 Added 0.29%
683 $237,000
Q2 2023

Jul 11, 2023

SELL
$314.42 - $351.91 $31,756 - $35,542
-101 Reduced 12.92%
681 $239,000
Q1 2023

Apr 07, 2023

BUY
$283.23 - $323.1 $24,641 - $28,109
87 Added 12.52%
782 $246,000
Q4 2022

Feb 02, 2023

BUY
$285.76 - $321.48 $198,603 - $223,428
695 New
695 $200,000
Q2 2022

Jul 11, 2022

SELL
$234.96 - $292.55 $70,957 - $88,350
-302 Reduced 29.35%
727 $209,000
Q1 2022

Apr 22, 2022

SELL
$221.42 - $260.97 $9,963 - $11,743
-45 Reduced 4.19%
1,029 $291,000
Q4 2021

Jan 26, 2022

SELL
$177.01 - $223.45 $39,296 - $49,605
-222 Reduced 17.13%
1,074 $245,000
Q3 2021

Oct 28, 2021

BUY
$181.39 - $202.99 $1,813 - $2,029
10 Added 0.78%
1,296 $236,000
Q2 2021

Aug 13, 2021

BUY
$187.49 - $221.1 $6,187 - $7,296
33 Added 2.63%
1,286 $253,000
Q1 2021

May 25, 2021

BUY
$207.02 - $241.31 $2,691 - $3,137
13 Added 1.05%
1,253 $267,000
Q4 2020

Jan 27, 2021

BUY
$207.01 - $276.09 $38,089 - $50,800
184 Added 17.42%
1,240 $288,000
Q3 2020

Oct 23, 2020

BUY
$255.65 - $303.1 $93,823 - $111,237
367 Added 53.27%
1,056 $227,000
Q2 2020

Jul 21, 2020

BUY
$225.48 - $295.8 $155,355 - $203,806
689 New
689 $203,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track 180 Wealth Advisors, LLC Portfolio

Follow 180 Wealth Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of 180 Wealth Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on 180 Wealth Advisors, LLC with notifications on news.